Sionna Therapeutics said its cystic fibrosis drug SION-719 failed to deliver benefit when added to Vertex’s Trikafta in a Phase 2 trial. The study did not show a statistically significant improvement in sweat chloride versus Trikafta alone, prompting Sionna to stop advancing the add-on approach and to preserve capital. The trial’s top-line readout undercut Sionna’s premise that its NBD1 stabilizer could normalize CFTR function beyond Vertex’s modulators. In early trading after the announcement, Sionna shares fell sharply, while Vertex shares rose. Sionna has now shifted away from that specific program, but the company is evaluating next steps following the negative result. The outcome further clarifies the difficulty of challenging Vertex’s established CF franchise through combination add-on mechanisms. For the market, the episode narrows the near-term competitive runway for oral CFTR-adjacent strategies and highlights how sensitive add-on trials can be to endpoint effect sizes.